These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 23720216)

  • 21. Development and validation of a prognostic nomogram for terminally ill cancer patients.
    Feliu J; Jiménez-Gordo AM; Madero R; Rodríguez-Aizcorbe JR; Espinosa E; Castro J; Acedo JD; Martínez B; Alonso-Babarro A; Molina R; Cámara JC; García-Paredes ML; González-Barón M
    J Natl Cancer Inst; 2011 Nov; 103(21):1613-20. PubMed ID: 21972226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM; Figlin RA; Hutson TE; Michaelson MD; Kim ST; Baum CM; Kattan MW
    Cancer; 2008 Oct; 113(7):1552-8. PubMed ID: 18720362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group.
    Galsky MD; Hendricks R; Svatek R; Bangs R; Hoffman-Censits J; Clement J; Dreicer R; Guancial E; Hahn N; Lerner SP; O'Donnell PH; Quale DZ; Siefker-Radtke A; Shipley W; Sonpavde G; Vaena D; Vinson J; Rosenberg J
    Cancer; 2013 Jun; 119(11):1994-8. PubMed ID: 23456777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.
    Lee CK; Hudson M; Stockler M; Coates AS; Ackland S; Gebski V; Lord S; Friedlander M; Boyle F; Simes RJ
    Breast Cancer Res Treat; 2011 Sep; 129(2):467-76. PubMed ID: 21445568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of a nomogram for predicting outcome of patients with vulvar cancer.
    Rouzier R; Preti M; Haddad B; Martin M; Micheletti L; Paniel BJ
    Obstet Gynecol; 2006 Mar; 107(3):672-7. PubMed ID: 16507940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder.
    Nakagawa T; Taguchi S; Uemura Y; Kanatani A; Ikeda M; Matsumoto A; Yoshida K; Kawai T; Nagata M; Yamada D; Komemushi Y; Suzuki M; Enomoto Y; Nishimatsu H; Ishikawa A; Nagase Y; Kondo Y; Tanaka Y; Okaneya T; Hirano Y; Shinohara M; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
    Urol Oncol; 2017 Jul; 35(7):457.e15-457.e21. PubMed ID: 28110856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
    Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
    Rouzier R; Pusztai L; Delaloge S; Gonzalez-Angulo AM; Andre F; Hess KR; Buzdar AU; Garbay JR; Spielmann M; Mathieu MC; Symmans WF; Wagner P; Atallah D; Valero V; Berry DA; Hortobagyi GN
    J Clin Oncol; 2005 Nov; 23(33):8331-9. PubMed ID: 16293864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies.
    Sherif A; Holmberg L; Rintala E; Mestad O; Nilsson J; Nilsson S; Malmström PU;
    Eur Urol; 2004 Mar; 45(3):297-303. PubMed ID: 15036674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis.
    Seisen T; Colin P; Hupertan V; Yates DR; Xylinas E; Nison L; Cussenot O; Neuzillet Y; Bensalah K; Novara G; Montorsi F; Zigeuner R; Remzi M; Shariat SF; Rouprêt M
    BJU Int; 2014 Nov; 114(5):733-40. PubMed ID: 24447471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.
    Schrier BP; Peters M; Barentsz JO; Witjes JA
    Eur Urol; 2006 Apr; 49(4):698-703. PubMed ID: 16464531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
    Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
    Raj GV; Iasonos A; Herr H; Donat SM
    J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.